


topical compositions, containing, respectively, betulinic acid and Vitamin D analogues, for treating melanoma. The Examiner has indicated allowability of claims 6, 10-13, 15, 19, 22, 25 and 28.

Although Applicants continue to disagree with the Examiner's position regarding the obviousness of the rejected claims, in order to advance prosecution of the present application, Applicants have rewritten claims 6, 10, and 15, each indicated as allowable, to incorporate the subject matter of the rejected base claim 1, and read as independent claims; the remaining claims have either been cancelled or amended to depend, directly or indirectly, from one of these independent claims containing allowable subject matter. More specifically, claims 2, 3, 4, 7, 8, 9, 16, 17, 18, 20, 21 and 23 now depend directly or indirectly from allowable claim 6; claims 11-13, 19, 22, 25, and 26 depend directly or indirectly from allowable claim 10; and claim 28 depends from allowable claim 15. Newly added claims 29-36 identically reflect the subject matter of original claims 2-9, written to depend from allowable claim 10. The remaining rejected claims have been cancelled. Applicants reserve the right to pursue any cancelled subject matter in one or more continuing applications. However, in view of the amendments to the claims herein, it is believed that the remaining amended claims are now all allowable.

CONCLUSION

The present claims are believed to be in condition for allowance, and prompt issuance of a Notice of Allowance is respectfully solicited. The Examiner is encouraged to contact the undersigned by telephone if it is believed that discussion will resolve any outstanding issues.

Respectfully submitted,


Karen A. Lowney, Reg. No. 31,274
Estee Lauder Companies
125 Pinelawn Road
Melville, NY 11747
(631)531-1191

COPY OF CLAIMS MARKED TO SHOW CHANGES

1(cancelled). A composition for topical application to the skin comprising effective amounts of at least one protease inhibitor and at least one cell differentiation enhancer.

2(amended). The composition of claim [1] 6 in which the protease inhibitor is selected from the group consisting of triterpenoid-containing extracts, and active components thereof, phenolic-containing extracts and active components thereof, and protein-based extract and active components thereof.

3(amended). The composition of claim [1] 6 in which the protease inhibitor is selected from the group consisting of white birch extract, silver birch extract, *Boswellia* extract, bearberry extract, *Centella asiatica* extract, *Pygeum (Prunus) africanum* extract, betulinol, betulinic acid, boswellic acid, ursolic acid, oleanolic acid, oleanol, asiaticoside, asiatic acid, madagassic acid, green tea extract, apple extracts, EGCG, ECG, catechins, phenylpropanoids, phloretin, soy protein, egg protease inhibitors, cholesterol sulfate, phytosterol sulfate, and combinations thereof.

4(unchanged). The composition of claim 3 in which the protease inhibitor is selected from the group consisting of white birch extract, betulinol, betulinic acid, *Boswellia* extract, boswellic acid, and combinations thereof.

5(cancelled). The composition of claim 1 in which the cell differentiation enhancer is selected from the group consisting of forskolin, sclareolide, 7-dehydrocholesterol, and Vitamin D3 analogs.

6(amended). [The composition of claim 5] A composition for topical application to the skin comprising effective amounts of at least one protease inhibitor and at least one cell differentiation enhancer, in which the enhancer is sclareolide .

7(amended). The composition of claim [1] 6 comprising about .001 to about 10% of a protease inhibitor and about 0.001-10% cell differentiation enhancer.

8(amended). The composition of claim [1] 6 comprising about 0.1 to about 1% of a protease inhibitor and about .05-1% cell differentiation enhancer.

9(unchanged). The composition of claim 8 in which the inhibitor is white birch extract, betulinol, or boswellic acid and the enhancer is sclareolide.

10(amended). [The composition of claim 1] A composition for topical application to the skin comprising effective amounts of at least one protease inhibitor and at least one cell differentiation enhancer, which also contains cholesterol sulfate.

11(unchanged). The composition of claim 10 which also contains at least one fatty acid, at least one ceramide, and at least one sterol.

12(unchanged). The composition of claim 11 in which the fatty acid is a C12-C20 fatty acid.

13(unchanged). The composition of claim 11 containing about 0.05 to 10% of each of cholesterol sulfate or phytosterol sulfate, fatty acid, ceramide, and sterol.

14(cancelled). The composition of claim 1 which further comprises an effective amount of at least one self-tanning agent.

15(amended). [The composition of claim 14] A composition for topical application to the skin comprising effective amounts of at least one protease inhibitor and at least one cell differentiation enhancer, which further comprises an effective amount of at least one self-tanning agent, in which the self-tanning agent is DHA.

16(amended). The composition of claim [1] 6 which further comprises at least one sunscreen.

17(amended). A method for treatment or prevention of dry skin which comprises applying to the skin a composition according to claim [1] 6.

18(unchanged). A method for treatment or prevention of dry skin which comprises applying to the skin a composition according to claim 9.

19(unchanged). A method for treatment or prevention of dry skin which comprises applying to the skin a composition according to claim 11.

20(amended). A method for reducing or preventing skin's response to irritants or sensitizers comprising applying to the skin a composition of claim [1] 6.

21(unchanged). A method for reducing or preventing skin's response to irritants or sensitizers comprising applying to the skin a composition of claim 9.

22(unchanged). A method for reducing or preventing skin's response to irritants or sensitizers comprising applying to the skin a composition of claim 11.

23(amended). A method for protecting skin against effects of exposure to UV radiation comprising applying to the skin a composition of claim [1] 6.

24(unchanged). A method for protecting skin against effects of exposure to UV radiation comprising applying to the skin a composition of claim 9.

25(unchanged). A method for protecting skin against effects of exposure to UV radiation comprising applying to the skin a composition of claim 11.

26(unchanged). A method for protecting skin against effects of exposure to UV radiation comprising applying to the skin a composition of claim 16.

27(cancelled). A method for tanning the skin without exposure to the sun comprising applying to the skin a composition according to claim 14.

28(unchanged). A method for tanning the skin without exposure to the sun comprising applying to the skin a composition according to claim 15.

29(new). The composition of claim 10 in which the protease inhibitor is selected from the group consisting of triterpenoid-containing extracts, and active components thereof, phenolic-containing extracts and active components thereof, and protein-based extract and active components thereof.

30(new). The composition of claim 10 in which the protease inhibitor is selected from the group consisting of white birch extract, silver birch extract, *Boswellia* extract, bearberry extract, *Centella asiatica* extract, *Pygeum (Prunus) africanum* extract, betulinol, betulinic acid, boswellic acid, ursolic acid, oleanolic acid, oleanol, asiaticoside, asiatic acid, madagassic acid, green tea extract, apple extracts, EGCG, ECG, catechins, phenylpropanoids, phloretin, soy protein, egg protease inhibitors, cholesterol sulfate, phytosterol sulfate, and combinations thereof.

31(new). The composition of claim 30 in which the protease inhibitor is selected from the group consisting of white birch extract, betulinol, betulinic acid, *Boswellia* extract, boswellic acid, and combinations thereof.

32(new). The composition of claim 10 in which the cell differentiation enhancer is selected from the group consisting of forskolin, sclareolide, 7-dehydrocholesterol, and Vitamin D3 analogs.

33(new). The composition of claim 32 in which the enhancer is sclareolide.

34(new). The composition of claim 10 comprising about .001 to about 10% of a protease inhibitor and about 0.001-10% cell differentiation enhancer.

35(new). The composition of claim 10 comprising about 0.1 to about 1% of a protease inhibitor and about .05-1% cell differentiation enhancer.

36(new). The composition of claim 35 in which the inhibitor is white birch extract, betulinol, or boswellic acid and the enhancer is sclareolide.